Home › Funds › Portolan Capital Management, LLC › CADL
Portolan Capital Management, LLC position in CADL
CANDEL THERAPEUTICS INC · Health Care
Portolan Capital Management, LLC reported holding 3,538,561 shares of CADL (CANDEL THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$36.9M, representing 1.54% of its reported portfolio and ranking #17 among its reported holdings. Portolan Capital Management, LLC has disclosed CADL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Portolan Capital Management, LLC's CADL position evolved
Portolan Capital Management, LLC first disclosed a stake in CADL in Q4 2024 at 753,745 shares (US$6.5M). The position peaked in Q3 2026 at 3,538,561 shares, worth US$36.9M. Across 8 filings, Portolan Capital Management, LLC increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,538,561 shares valued at US$36.9M — an increase of 48,163 shares quarter over quarter.. Notable position changes include a 84% increase in Q2 2025 (shares were roughly flat over the following quarter), a 71% increase in Q1 2026 (shares rose 110% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 753.75K | $6.54M | New |
| Q1 2025 | 881.18K | $4.98M | Add |
| Q2 2025 | 1.62M | $8.21M | Add |
| Q3 2025 | 1.38M | $7.06M | Reduce |
| Q4 2025 | 1.70M | $9.58M | Add |
| Q1 2026 | 2.89M | $14.18M | Add |
| Q2 2026 | 3.49M | $35.95M | Add |
| Q3 2026 | 3.54M | $36.94M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CADL and 13F data
CADL (CANDEL THERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in CADL — the largest reported positions include ACORN CAPITAL ADVISORS, LLC (US$36.5M), Saturn V Capital Management LP (US$36.3M), Sands Capital Alternatives, LLC (US$4.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CADL
- ACORN CAPITAL ADVISORS, LLC 3.50M sh · $36.52M · Q3 2026
- Saturn V Capital Management LP 3.48M sh · $36.29M · Q3 2026
- Sands Capital Alternatives, LLC 405.84K sh · $4.24M · Q3 2026
- Tanager Wealth Management LLP 198.18K sh · $2.07M · Q3 2026
- ACT Capital Partners, L.P. 150.50K sh · $1.57M · Q3 2026
More on Portolan Capital Management, LLC
FAQ
How long has Portolan Capital Management, LLC held CADL?
Portolan Capital Management, LLC has disclosed CADL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Portolan Capital Management, LLC's current position in CADL?
As of Q3 2026, Portolan Capital Management, LLC holds 3.54M shares of CADL (CANDEL THERAPEUTICS INC), valued at $36.94M, representing 1.54% of its reported portfolio and ranking #17.
Has Portolan Capital Management, LLC been buying or selling CADL?
In the latest 13F filing (Q3 2026), Portolan Capital Management, LLC increased its position in CADL. The position peaked in Q3 2026 at 3.54M shares.
Which other funds hold CADL?
Other major institutional holders of CADL include ACORN CAPITAL ADVISORS, LLC, Saturn V Capital Management LP, Sands Capital Alternatives, LLC, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.